Meta-Analysis of Creatine for Neuroprotection Against Parkinson’s Disease

Author(s): Attia Attia, Hussien Ahmed, Mohamed Gadelkarim, Mahmoud Morsi, Kamal Awad, Mohamed Elnenny, Esraa Ghanem, Shaimaa El-Jaafary, Ahmed Negida.

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 16 , Issue 2 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Creatine is an antioxidant agent that showed neuroprotective effects in animal models of Parkinson’s disease (PD). Creatine was selected by the National Institute of Neurological Disorders and Stroke as a possible disease modifying agent for Parkinson's disease. Therefore, many clinical trials evaluated the efficacy of creatine for patients with PD. The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of Creatine for patients with PD.

Methods: We followed PRISMA statement guidelines during the preparation of this systematic review and meta-analysis. A computer literature search for PubMed, EBSCO, web of science and Ovid Midline was carried out. We included RCTs comparing creatine with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, and UPDRS III were pooled as mean difference (MD) between two groups from baseline to the endpoint. Statistical heterogeneity was assessed by visual inspection of the forest plot and measured by chi-square and I square tests.

Results: Three RCTs (n=1935) were included in this study. The overall effect did not favor either of the two groups in terms of: UPDRS total score (MD 1.07, 95% CI [3.38 to 1.25], UPDRS III (MD 0.62, 95% CI [2.27 to 1.02]), UPDRS II (MD 0.03, 95% CI [0.81 to 0.86], or UPDRS I (MD 0.03, 95% CI [0.33 to 0.28]).

Conclusion: Current evidence does not support the use of creatine for neuroprotection against PD. Future well-designed, randomized controlled trials are needed.

Keywords: Neuroprotection, Parkinson's disease, Parkinson's disease.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 2
Year: 2017
Page: [169 - 175]
Pages: 7
DOI: 10.2174/1871527315666161104161855
Price: $58

Article Metrics

PDF: 31
HTML: 2